Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib in Refractory or Relapsed AML
NCT00354146Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2001
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of tipifarnib in acute myeloid leukemia (AML) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Rate of Complete Remission or Complete Remission with Incomplete Platelet Recovery. Started Apr 2001; status: completed.
02
Drugs
tipifarnib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00354146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354146.